NVS is IDIX’s partner and they don’t screw up very often. Moreover, Telbivudine/Sebivo/Tyzeka had already been approved in Switzerland using essentially the same data package that was submitted to the FDA. So this was a pretty low-risk NDA.
The question now is whether NVS and IDIX can expand the HBV market and capture substantial share from the incumbents. I’m betting that they can.
Market Data 
Markets 
AI
